ConductScience.org, home
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
API referenceFor AI assistants

Trial · NCT03242018

Adverse events258

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

141 to 160 of 258

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
seriousPulmonary congestionRespiratory, thoracic and mediastinal disordersSotagliflozin 400 mg190
seriousPulmonary hypertensionRespiratory, thoracic and mediastinal disordersPlacebo093
seriousPulmonary hypertensionRespiratory, thoracic and mediastinal disordersSotagliflozin 200 mg194
seriousPulmonary hypertensionRespiratory, thoracic and mediastinal disordersSotagliflozin 400 mg090
seriousPulmonary oedemaRespiratory, thoracic and mediastinal disordersPlacebo093
seriousPulmonary oedemaRespiratory, thoracic and mediastinal disordersSotagliflozin 200 mg094
seriousPulmonary oedemaRespiratory, thoracic and mediastinal disordersSotagliflozin 400 mg290
seriousTracheomalaciaRespiratory, thoracic and mediastinal disordersPlacebo193
seriousTracheomalaciaRespiratory, thoracic and mediastinal disordersSotagliflozin 200 mg094
seriousTracheomalaciaRespiratory, thoracic and mediastinal disordersSotagliflozin 400 mg090
seriousAnaemiaBlood and lymphatic system disordersPlacebo193
seriousAnaemiaBlood and lymphatic system disordersSotagliflozin 200 mg094
seriousAnaemiaBlood and lymphatic system disordersSotagliflozin 400 mg090
seriousBlood loss anaemiaBlood and lymphatic system disordersPlacebo193
seriousBlood loss anaemiaBlood and lymphatic system disordersSotagliflozin 200 mg094
seriousBlood loss anaemiaBlood and lymphatic system disordersSotagliflozin 400 mg090
seriousIschaemic strokeNervous system disordersPlacebo193
seriousIschaemic strokeNervous system disordersSotagliflozin 200 mg094
seriousIschaemic strokeNervous system disordersSotagliflozin 400 mg090
seriousPeripheral sensorimotor neuropathyNervous system disordersPlacebo093

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03242018/events?page=8

API referenceFor AI assistants